» Articles » PMID: 32911134

Interest in Reducing Methamphetamine and Opioid Use Among Syringe Services Program Participants in Washington State

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2020 Sep 10
PMID 32911134
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Methamphetamine use is increasing, and opioid use remains elevated in the US. Understanding interest in reducing/stopping substance use among people who inject drugs (PWID), as well as types of help wanted, can inform interventions.

Methods: Data from the 2019 Washington State Syringe Exchange Survey were used in logistic regression analyses to assess if demographics, substance use, and concern about anxiety or depression were associated with interest in reducing/stopping substance use among people whose main drug was methamphetamine or opioids. Types of help wanted to reduce/stop use are reported.

Results: Of 583 participants included, 76 % reported opioids were their main drug, of whom 82 % were interested in reducing/stopping their opioid use. 24 % reported methamphetamine as their main drug, of whom 46 % were interested in reducing/stopping their methamphetamine use. Among those whose main drug was an opioid, female gender (AOR:2.19, p = .023) and concern about depression (AOR:3.04, p = .002) were associated with interest in reducing/stopping opioid use. Among participants whose main drug was methamphetamine, being in jail in the past year and having an infection likely related to injection (e.g., abscess) in the past year were associated with over twice the odds of interest in reducing/stopping methamphetamine use (AOR:2.14, p = .056 and 2.43, p = .052, respectively); however, these findings were not significant. Several types of help to reduce/stop use were endorsed.

Conclusion: There were high, though differing, levels of interest in reducing/stopping opioid or methamphetamine use and in a range of support services. PWID should be asked about interest in reducing/stopping use and provided appropriate support.

Citing Articles

Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes.

Banta-Green C, Owens M, Williams J, Floyd A, Williams-Gilbert W, Kingston S Subst Abuse Rehabil. 2024; 15:173-183.

PMID: 39295965 PMC: 11409926. DOI: 10.2147/SAR.S475807.


Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont.

Erath T, LaCroix R, OKeefe E, Higgins S, Rawson R Harm Reduct J. 2024; 21(1):76.

PMID: 38580997 PMC: 10998322. DOI: 10.1186/s12954-024-00995-y.


A qualitative study of people who use methamphetamine during the early COVID-19 pandemic to inform future ED harm reduction strategies.

Morse S, Fockele C, Huynh L, Zatzick A, Whiteside L Int J Emerg Med. 2023; 16(1):30.

PMID: 37106338 PMC: 10139825. DOI: 10.1186/s12245-023-00505-0.


"That Line Just Kept Moving": Motivations and Experiences of People Who Use Methamphetamine.

Fockele C, Morse S, Van Draanen J, Leyde S, Banta-Green C, Huynh L West J Emerg Med. 2023; 24(2):218-227.

PMID: 36976607 PMC: 10047723. DOI: 10.5811/westjem.2022.12.58396.


The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.

Banta-Green C, Owens M, Williams J, Sears J, Floyd A, Williams-Gilbert W Addict Sci Clin Pract. 2022; 17(1):34.

PMID: 35799210 PMC: 9261214. DOI: 10.1186/s13722-022-00315-4.


References
1.
Applewhite D, Regan S, Koenigs K, Mackin S, Schmidt C, Wakeman S . Use of promethazine, gabapentin and clonidine in combination with opioids or opioid agonist therapies among individuals attending a syringe service program. Int J Drug Policy. 2020; 79:102752. DOI: 10.1016/j.drugpo.2020.102752. View

2.
Korte J, Hiott F, Brady K, Malcolm R, See R . Distinctive characteristics of methamphetamine users presenting at public clinics: steep rise in South Carolina, United States, 2000-2005. Drug Alcohol Depend. 2010; 115(1-2):9-15. PMC: 3081922. DOI: 10.1016/j.drugalcdep.2010.09.023. View

3.
Coffin P, Santos G, Hern J, Vittinghoff E, Walker J, Matheson T . Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. JAMA Psychiatry. 2019; 77(3):246-255. PMC: 6990973. DOI: 10.1001/jamapsychiatry.2019.3655. View

4.
Sullivan M . Depression Effects on Long-term Prescription Opioid Use, Abuse, and Addiction. Clin J Pain. 2018; 34(9):878-884. DOI: 10.1097/AJP.0000000000000603. View

5.
Salehi M, Emadossadat A, Kheirabadi G, Maracy M, Sharbafchi M . The Effect of Buprenorphine on Methamphetamine Cravings. J Clin Psychopharmacol. 2015; 35(6):724-7. DOI: 10.1097/JCP.0000000000000408. View